{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:33:11Z","timestamp":1793147591100,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The transcription factor MYC is deregulated in almost all human cancers, especially in aggressive lymphomas, through chromosomal translocation, amplification, and transcription hyperactivation. Here, we report that high expression of tribbles homologue 3 (TRIB3) positively correlates with elevated MYC expression in lymphoma specimens; <jats:italic>TRIB3<\/jats:italic> deletion attenuates the initiation and progression of MYC-driven lymphoma by reducing MYC expression. Mechanistically, TRIB3 interacts with MYC to suppress E3 ubiquitin ligase UBE3B-mediated MYC ubiquitination and degradation, which enhances MYC transcriptional activity, causing high proliferation and self-renewal of lymphoma cells. Use of a peptide to disturb the TRIB3-MYC interaction together with doxorubicin reduces the tumor burden in <jats:italic>Myc<\/jats:italic><jats:sup>E\u03bc<\/jats:sup> mice and patient-derived xenografts. The pathophysiological relevance of UBE3B, TRIB3 and MYC is further demonstrated in human lymphoma. Our study highlights a key mechanism for controlling MYC expression and a potential therapeutic option for treating lymphomas with high TRIB3-MYC expression.<\/jats:p>","DOI":"10.1038\/s41467-020-20107-1","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T11:39:11Z","timestamp":1607513951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation"],"prefix":"10.1038","volume":"11","author":[{"given":"Ke","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-fen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-xi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiwuli","family":"Yeerjiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-7801","authenticated-orcid":false,"given":"Bing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6214-1384","authenticated-orcid":false,"given":"Fang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-6980","authenticated-orcid":false,"given":"Xiao-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao-jiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-5601","authenticated-orcid":false,"given":"Jin-mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-9371","authenticated-orcid":false,"given":"Zhuo-wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"20107_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J. Clin. Oncol. 32, 3059\u20133067 (2014).","journal-title":"J. Clin. Oncol."},{"key":"20107_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland, K. R., Armitage, J. O. & Hancock, B. W. Non-Hodgkin lymphoma. Lancet 380, 848\u2013857 (2012).","journal-title":"Lancet"},{"key":"20107_CR3","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","volume":"33","author":"V Minard-Colin","year":"2015","unstructured":"Minard-Colin, V. et al. Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J. Clin. Oncol. 33, 2963\u20132974 (2015).","journal-title":"J. Clin. Oncol."},{"key":"20107_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11912-009-0052-0","volume":"11","author":"C Thieblemont","year":"2009","unstructured":"Thieblemont, C. & Gisselbrecht, C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr. Oncol. Rep. 11, 386\u2013393 (2009).","journal-title":"Curr. Oncol. Rep."},{"key":"20107_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024\u20131039 (2015).","journal-title":"Cancer Discov."},{"key":"20107_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"ChiV Dang","year":"2012","unstructured":"Dang, ChiV. MYC on the path to cancer. Cell 149, 22\u201335 (2012).","journal-title":"Cell"},{"key":"20107_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.ge.20.120186.002045","volume":"20","author":"MD Cole","year":"1986","unstructured":"Cole, M. D. The myc oncogene: its role in transformation and differentiation. Annu. Rev. Genet. 20, 361\u2013384 (1986).","journal-title":"Annu. Rev. Genet."},{"key":"20107_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature13537","volume":"511","author":"A Sabo","year":"2014","unstructured":"Sabo, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488\u2013492 (2014).","journal-title":"Nature"},{"key":"20107_CR9","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824\u20137827 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20107_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","volume":"22","author":"S Sander","year":"2012","unstructured":"Sander, S. et al. Synergy between PI3K signaling and MYC in burkitt lymphomagenesis. Cancer Cell 22, 167\u2013179 (2012).","journal-title":"Cancer Cell"},{"key":"20107_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2141.2008.07152.x","volume":"142","author":"HY O.","year":"2008","unstructured":"O., H. Y. et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br. J. Haematol. 142, 36\u201344 (2008).","journal-title":"Br. J. Haematol."},{"key":"20107_CR12","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040\u20131050 (2014).","journal-title":"Blood"},{"key":"20107_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1210\/me.2008-0284","volume":"23","author":"K Du","year":"2009","unstructured":"Du, K. & Ding, J. Insulin regulates TRB3 and other stress-responsive gene expression through induction of C\/EBPbeta. Mol. Endocrinol. 23, 475\u2013485 (2009).","journal-title":"Mol. Endocrinol."},{"key":"20107_CR14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1161\/CIRCRESAHA.109.211920","volume":"106","author":"J Avery","year":"2010","unstructured":"Avery, J. et al. TRB3 function in cardiac endoplasmic reticulum stress. Circ. Res. 106, 1516\u20131523 (2010).","journal-title":"Circ. Res."},{"key":"20107_CR15","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1172\/JCI36849","volume":"120","author":"CW Liew","year":"2010","unstructured":"Liew, C. W. et al. The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells. J. Clin. Invest. 120, 2876\u20132888 (2010).","journal-title":"J. Clin. Invest."},{"key":"20107_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1126\/science.1079817","volume":"300","author":"K Du","year":"2003","unstructured":"Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt\/PKB activation by insulin in liver. Science 300, 1574\u20131577 (2003).","journal-title":"Science"},{"key":"20107_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8951","volume":"6","author":"F Hua","year":"2015","unstructured":"Hua, F. et al. TRB3 links insulin\/IGF to tumour promotion by interacting with p62 and impeding autophagic\/proteasomal degradations. Nat. Commun. 6, 7951 (2015).","journal-title":"Nat. Commun."},{"key":"20107_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccell.2017.04.006","volume":"31","author":"K Li","year":"2017","unstructured":"Li, K. et al. TRIB3 promotes APL progression through stabilization of the oncoprotein PML-RARa and inhibition of p53-mediated senescence. Cancer Cell 31, 697\u2013710.e697 (2017).","journal-title":"Cancer Cell"},{"key":"20107_CR19","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41388-018-0172-9","volume":"37","author":"K Li","year":"2018","unstructured":"Li, K. et al. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene 37, 2967\u20132981 (2018).","journal-title":"Oncogene"},{"key":"20107_CR20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/onc.2016.276","volume":"36","author":"J Izrailit","year":"2017","unstructured":"Izrailit, J., Jaiswal, A., Zheng, W., Moran, M. F. & Reedijk, M. Cellular stress induces TRB3\/USP9x-dependent Notch activation in cancer. Oncogene 36, 1048\u20131057 (2017).","journal-title":"Oncogene"},{"key":"20107_CR21","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3892\/or.2016.5017","volume":"36","author":"S Dong","year":"2016","unstructured":"Dong, S. et al. Overexpression of TRIB3 promotes angiogenesis in human gastric cancer. Oncol. Rep. 36, 2339\u20132348 (2016).","journal-title":"Oncol. Rep."},{"key":"20107_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/j.gastro.2018.10.031","volume":"156","author":"F Hua","year":"2019","unstructured":"Hua, F. et al. TRIB3 interacts with \u03b2-catenin and TCF4 to increase stem cell features of colorectal cancer stem cells and tumorigenesis. Gastroenterology 156, 708\u2013721.e715 (2019).","journal-title":"Gastroenterology"},{"key":"20107_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2141.2012.09222.x","volume":"158","author":"MM Hannon","year":"2012","unstructured":"Hannon, M. M. et al. Elevated TRIB2 with NOTCH1 activation in paediatric\/adult T-ALL. Br. J. Haematol. 158, 626\u2013634 (2012).","journal-title":"Br. J. Haematol."},{"key":"20107_CR24","doi-asserted-by":"publisher","first-page":"15050","DOI":"10.1038\/celldisc.2015.50","volume":"2","author":"KL Liang","year":"2016","unstructured":"Liang, K. L., O\u2019Connor, C., Veiga, J. P., McCarthy, T. V. & Keeshan, K. TRIB2 regulates normal and stress-induced thymocyte proliferation. Cell Discov. 2, 15050 (2016).","journal-title":"Cell Discov."},{"key":"20107_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fimmu.2018.00373","volume":"9","author":"L Simoni","year":"2018","unstructured":"Simoni, L. et al. Trib1 is overexpressed in systemic lupus erythematosus, while it regulates immunoglobulin production in murine B cells. Front. Immunol. 9, 373 (2018).","journal-title":"Front. Immunol."},{"key":"20107_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the \u2018undruggable\u2019 cancer targets. Nat. Rev. Cancer 17, 502\u2013508 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"20107_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-pharmtox-010715-103440","volume":"56","author":"JS Lazo","year":"2016","unstructured":"Lazo, J. S. & Sharlow, E. R. Drugging undruggable molecular cancer targets. Annu. Rev. Pharmacol. Toxicol. 56, 23\u201340 (2016).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"20107_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fcell.2017.00010","volume":"5","author":"JR Whitfield","year":"2017","unstructured":"Whitfield, J. R., Beaulieu, M. E. & Soucek, L. Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol. 5, 10 (2017).","journal-title":"Front. Cell Dev. Biol."},{"key":"20107_CR29","first-page":"3507","volume":"62","author":"L Soucek","year":"2002","unstructured":"Soucek, L. et al. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62, 3507\u20133510 (2002).","journal-title":"Cancer Res."},{"key":"20107_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","volume":"24","author":"M Brockmann","year":"2013","unstructured":"Brockmann, M. et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24, 75\u201389 (2013).","journal-title":"Cancer Cell"},{"key":"20107_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.15252\/emmm.201403927","volume":"6","author":"S Peter","year":"2014","unstructured":"Peter, S. et al. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase. EMBO Mol. Med. 6, 1525\u20131541 (2014).","journal-title":"EMBO Mol. Med."},{"key":"20107_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"20107_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-12-0066","volume":"11","author":"HL Huang","year":"2012","unstructured":"Huang, H. L. et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol. Cancer Ther. 11, 1155\u20131165 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"20107_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122\u2013128 (2015).","journal-title":"Drug Discov. Today"},{"key":"20107_CR35","doi-asserted-by":"crossref","unstructured":"Dejure, F. R. et al. The MYC mRNA 3\u2032\u2010UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. EMBO J 36, 1854\u20131868 (2017).","DOI":"10.15252\/embj.201796662"},{"key":"20107_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.gene.2011.12.027","volume":"494","author":"B L\u00fcscher","year":"2012","unstructured":"L\u00fcscher, B. & Vervoorts, J. Regulation of gene transcription by the oncoprotein MYC. Gene 494, 145\u2013160 (2012).","journal-title":"Gene"},{"key":"20107_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(00)80308-1","volume":"3","author":"R Sears","year":"1999","unstructured":"Sears, R., Leone, G., DeGregori, J. & Nevins, J. R. Ras enhances Myc protein stability. Mol. Cell 3, 169\u2013179 (1999).","journal-title":"Mol. Cell"},{"key":"20107_CR38","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501\u20132514 (2000).","journal-title":"Genes Dev."},{"key":"20107_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.celrep.2015.07.003","volume":"12","author":"K Myant","year":"2015","unstructured":"Myant, K. et al. Serine 62-phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for regenerative proliferation. Cell Rep. 12, 1019\u20131031 (2015).","journal-title":"Cell Rep."},{"key":"20107_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/0008-5472.CAN-10-1032","volume":"71","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. Phosphorylation regulates c-Myc\u2019s oncogenic activity in the mammary gland. Cancer Res. 71, 925\u2013936 (2011).","journal-title":"Cancer Res."},{"key":"20107_CR41","first-page":"a014365","volume":"4","author":"AS Farrell","year":"2014","unstructured":"Farrell, A. S. & Sears, R. C. MYC degradation. CSH Perspect. Med. 4, a014365 (2014).","journal-title":"CSH Perspect. Med."},{"key":"20107_CR42","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.str.2015.08.017","volume":"23","author":"JM Murphy","year":"2015","unstructured":"Murphy, J. M. et al. Molecular mechanism of CCAAT-enhancer binding protein recruitment by the TRIB1 pseudokinase. Structure 23, 2111\u20132121 (2015).","journal-title":"Structure"},{"key":"20107_CR43","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.28382","volume":"134","author":"K Li","year":"2014","unstructured":"Li, K. et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int. J. Cancer 134, 692\u2013702 (2014).","journal-title":"Int. J. Cancer"},{"key":"20107_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0467-3","volume":"9","author":"M Salome","year":"2018","unstructured":"Salome, M. et al. A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death Dis. 9, 443 (2018).","journal-title":"Cell Death Dis."},{"key":"20107_CR45","doi-asserted-by":"publisher","first-page":"e0155408","DOI":"10.1371\/journal.pone.0155408","volume":"11","author":"SJ Stein","year":"2016","unstructured":"Stein, S. J. et al. Trib2 suppresses tumor initiation in notch-driven T-ALL. PLoS ONE 11, e0155408 (2016).","journal-title":"PLoS ONE"},{"key":"20107_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2006.09.012","volume":"10","author":"K Keeshan","year":"2006","unstructured":"Keeshan, K. et al. Tribbles homolog 2 inactivates C\/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 10, 401\u2013411 (2006).","journal-title":"Cancer Cell"},{"key":"20107_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.molcel.2013.05.013","volume":"51","author":"J Wang","year":"2013","unstructured":"Wang, J. et al. TRIB2 acts downstream of Wnt\/TCF in liver cancer cells to regulate YAP and C\/EBPalpha function. Mol. Cell 51, 211\u2013225 (2013).","journal-title":"Mol. Cell"},{"key":"20107_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","volume":"23","author":"L Reavie","year":"2013","unstructured":"Reavie, L. et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23, 362\u2013375 (2013).","journal-title":"Cancer Cell"},{"key":"20107_CR49","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.yexcr.2009.01.011","volume":"315","author":"AA Chakraborty","year":"2009","unstructured":"Chakraborty, A. A. & Tansey, W. P. Inference of cell cycle-dependent proteolysis by laser scanning cytometry. Exp. Cell Res. 315, 1772\u20131778 (2009).","journal-title":"Exp. Cell Res."},{"key":"20107_CR50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ajhg.2012.10.011","volume":"91","author":"L Basel-Vanagaite","year":"2012","unstructured":"Basel-Vanagaite, L. et al. Deficiency for the ubiquitin ligase UBE3B in a blepharophimosis-ptosis-intellectual-disability syndrome. Am. J. Hum. Genet. 91, 998\u20131010 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"20107_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu, G., Belkina, A. C. & Denis, G. V. Clinical trials for BET inhibitors run ahead of the science. Drug Discov. Today Technol. 19, 45\u201350 (2016).","journal-title":"Drug Discov. Today Technol."},{"key":"20107_CR52","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","volume":"17","author":"L Soucek","year":"1998","unstructured":"Soucek, L. et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17, 2463\u20132472 (1998).","journal-title":"Oncogene"},{"key":"20107_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538\u2013542 (2015).","journal-title":"Nature"},{"key":"20107_CR54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543\u2013547 (2015).","journal-title":"Nature"},{"key":"20107_CR55","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. & Altman, D. G. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 160, 1577\u20131579 (2010).","journal-title":"Br. J. Pharmacol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20107-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:21:42Z","timestamp":1670293302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20107-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["20107"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20107-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6316"}}